Navegando por Palavras-chave "Função jurisdicional"

Agora exibindo 1 - 1 de 1
  • Imagem de Miniatura
    Item
    Acesso aberto (Open Access)
    Judicialização da Saúde: Características das ações judiciais recebidas na Secretaria de Ciência, Tecnologia e Insumos Estratégicos do Ministério da Saúde no ano de 2007
    (Universidade Federal de São Paulo (UNIFESP), 2011-01-26) Veloso, Sandra Ceciliano de Souza [UNIFESP]; Silva, Edina Mariko Koga da [UNIFESP]; Universidade Federal de São Paulo (UNIFESP)
    Introduction: Currently, the two largest financial resources demands for pharmaceutical assistance are exceptional medicines programme and legal demands service for the supply of medicines. The legal demands, and disrupt the service, commitment to fairness and collective contradict definitions. Therefore, it’s a priority a study that describes the characteristics of these actions to subsidize public health policies. Objective: To describe the characteristics of lawsuits received at the Secretary of Science, Technology and Strategic Inputs (SCTIE) of the Ministry of Health in the year 2007. Material and methods: A descriptive analysis that covers the total shares received in the year 2007. Were evaluated the distribution by State, the characteristics of requests, classification of medicines as the availability and regulatory and scientific evidence considerations. Results: In 2007 were received on the SCTIE 832 litigation processes. These actions were from 20 States of the Federation, being the largest number of actions, 207 (24,88%), from the State of Santa Catarina, followed by the State of Rio Grande do Sul with 127 (15,14%). Including the actions from the State of Paraná, the South region of the country totaled stock received 50,72% in 2007. Of the total of 832 actions 444 (53,37%) were requests for specific products or medicines. These are only two medical devices, the others are medicines. Most requested medicines were adalimumab and etanercept which together correspond to 16,89% of total requests and were generated by southern states in its majority. The 11 most requested medicines represent 47.07% of the total. In general the medicines indications were as regulation and are indicated for chronic diseases, two were not registered at ANVISA yet. The eleven medicines most requested were not found in the national essential medicines (RENAME) and 3 (three), adalimumab, etanercept and infliximab were already part of the exceptional dispensing medicines (CDME). Regarding the scientific evidence was found that for most medicines would need further studies for evidence of effectiveness, safety and cost-effectiveness. Conclusion: The analysis of lawsuits is needed for the evaluation of policies and management of health services and also to assist in identifying medicinal products for health technology assessment. Knowledge of the factors that lead to lawsuits medicines added approximation of judiciary with managers and health professionals can achieve the common goal of a quality public health, universal and comprehensive based on fairness.